Description
While novel TREM2 ligands have been identified and TREM2’s role in plaque maintenance is established, the specific ligand-receptor interactions that control microglial behavior around plaques are not mechanistically defined. This knowledge gap limits therapeutic targeting of microglial dysfunction.
Gap type: unexplained_observation Source paper: TREM2, Microglia, and Neurodegenerative Diseases. (2017, Trends in molecular medicine, PMID:28442216)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:45.460839+00:00”, “resolution_summary”: “Resolved by hypothesis h-d083850487: TREM2-dependent microglial phagocytosis of tau seeds. Supporting evidence includes debate sess_SDA-2026-04-13-gap-pubmed-20260410-110327-26e1d6c7.”, “match_counts”: {“hypothesis_matches”: 5, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-d083850487”, “title”: “TREM2-dependent microglial phagocytosis of tau seeds”, “score”: 0.337, “reason”: “7 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-26-gap-pubmed-20260410-150544-e3a2eab9-debate”, “target_gene”: “TREM2/Syk/PLCγ2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.53, “confidence_score”: 0.5, “status”: “proposed”, “pubmed_evidence_ids”: [“26653636”, “29518356”, “29689295”, “36306735”, “36564824”]}, {“id”: “h-44b1c9d415”, “title”: “TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer’s Disease”, “score”: 0.257, “reason”: “7 token overlaps; entity overlap: trem2”, “analysis_id”: “legacy-pre-pipeline-import-v1”, “target_gene”: “TREM2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.827427, “confidence_score”: 0.88, “status”: “proposed”, “pubmed_evidence_ids”: [“26741508”, “28165511”, “29196612”]}, {“id”: “h-var-799795f6af”, “title”: “TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming”, “score”: 0.249, “reason”: “21 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402”, “target_gene”: “TREM2, CSF1R”, “target_pathway”: “TREM2/CSF1R metabolic cross-talk → microglial metabolic dysfunction”, “disease”: “neurodegeneration”, “composite_score”: 0.748363, “confidence_score”: 0.78, “status”: “proposed”, “pubmed_evidence_ids”: [“20301376”, “24047521”, “28802038”, “30258234”, “31932797”]}, {“id”: “h-b9794c8e29”, “title”: “Microglial TREM2 Activation Reduces Amyloid-Associated Neurotoxicity”, “score”: 0.249, “reason”: “4 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-TEST-PREREG-003”, “target_gene”: “TREM2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.71, “confidence_score”: 0.78, “status”: “proposed”, “pubmed_evidence_ids”: [“24121985”, “29548884”, “31253634”, “32109293”]}, {“id”: “h-aa1f5de5cd”, “title”: “TREM2 haploinsufficiency dysregulates microglial synaptic surveillance, switching from protective ‘disease-associated microglia’ to neurotoxic ‘inflammasome-active’ states”, “score”: 0.241, “reason”: “19 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-02-gap-synaptic-pruning-microglia”, “target_gene”: “TREM2, TYROBP (DAP12), APOE”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.7, “confidence_score”: 0.22, “status”: “proposed”, “pubmed_evidence_ids”: [“26598730”, “27753624”, “28602351”, “28802038”, “29070674”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-110327-26e1d6c7”, “title”: “While the study shows HDAC1/2 deletion improves amyloid clearance and cognition, the specific epigenetic and transcriptional changes that enhance phagocytic function are not mechanistically defined. This knowledge gap limits translation to targeted therapeutic approaches.\n\nGap type: unexplained_observation\nSource paper: Histone Deacetylases 1 and 2 Regulate Microglia Function during Development, Homeostasis, and Neurodegeneration in a Context-Dependent Manner. (2018, Immunity, PMID:29548672)”, “score”: 0.504, “reason”: “14 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-110327-26e1d6c7”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-150500-e110aab9_20260413-225442”, “title”: “This study identifies oligodendrocytes as drivers of neuroinflammation in PD, contradicting the established paradigm that microglia are the primary neuroinflammatory cells. Understanding this cell-type hierarchy is crucial for targeting the right therapeutic cells.\n\nGap type: contradiction\nSource paper: Oligodendrocytes drive neuroinflammation and neurodegeneration in Parkinson’s disease via the prosaposin-GPR37-IL-6 axis. (2025, Cell Rep, PMID:39913287)”, “score”: 0.462, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-150500-e110aab9”, “quality_score”: 0.79, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-041439-306c2cdb_task_73907230”, “title”: “The abstract describes IBA1 low/negative microglia in individuals with liver disease but provides no mechanistic explanation for this phenomenon. This represents an unexplored brain-liver axis that could impact neuroinflammation and neurodegeneration.\n\nGap type: unexplained_observation\nSource paper: Beyond Activation: Characterizing Microglial Functional Phenotypes. (2021, Cells, PMID:34571885)”, “score”: 0.431, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-041439-306c2cdb”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-181258-df5eee45”, “title”: “The study shows that OB microglia phagocytose LC axons before amyloid plaque formation, but the molecular signals that mark these axons for destruction are unknown. Understanding this mechanism could reveal early therapeutic targets to prevent noradrenergic denervation.\n\nGap type: unexplained_observation\nSource paper: Early Locus Coeruleus noradrenergic axon loss drives olfactory dysfunction in Alzheimer’s disease. (2025, Nature communications, PMID:40781079)”, “score”: 0.421, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-181258-df5eee45”, “quality_score”: 0.7, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c”, “title”: “The abstract shows TYROBP deficiency is neuroprotective despite being required for TREM2, CD33, and CR3 function - receptors associated with AD risk. This counterintuitive finding challenges current understanding of how these immune receptors contribute to AD pathogenesis.\n\nGap type: contradiction\nSource paper: Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology. (None, None, PMID:28612290)”, “score”: 0.414, “reason”: “6 token overlaps; entity overlap: pmid, trem2”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c”, “quality_score”: 0.56, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}